Screening immunomodulatory agents by CTLA-4 upregulation

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007240, C435S040500, C424S009100

Reexamination Certificate

active

07014998

ABSTRACT:
Screens that directly or indirectly measure or qualitatively observe CTLA-4 expression or function by animals or cell cultures, or that indirectly measure dependence of an agent on CTLA-4 by comparison to animals or cell cultures that lack CTLA-4, identify agents that are useful in immunosuppression and the generation of immunologic tolerance for the prevention and treatment of transplant rejection, autoimmune and inflammatory diseases.

REFERENCES:
patent: 5434131 (1995-07-01), Linsley et al.
patent: 6024957 (2000-02-01), Lazarovits et al.
patent: 6084067 (2000-07-01), Freeman et al.
patent: 6099838 (2000-08-01), Lazarovits et al.
patent: 6106834 (2000-08-01), Lazarovits et al.
Xia et al. , CMLS Cell. Mul. Life. Sci. 55:1649-56, 1999.
Curreno et al, Journal of Immunology 165:1352-1356, 2000.
Harper et al. (J Immunol 1991 vol. 147(3) pp. 1037-1044).
Fecteau, S., et al., Nature Immunology 2: 58-63 (2001).
Rothstein, D., et al., J. ASN abstract (2000) “A New Paradigm for the Induction of Tolerance”.
Rothstein, D., et al., J. ASN abstract (2000) “Tolerance Induced Through Alteration of Signal One . . . ”.
Rothstein, D., and Basadonna, G., Graft 2: issue 6 immunosuppression review, Nov./Dec. 199: “Anti-CD45”.
Rothstein, D., et al., Journal of Immunology 166: 322-329 (2001).
Tian, J., et al., J. ASN abstract (2001) “CD-45 Mediation Upregulation of the CTLA-4 Inhibitory Receptor . . . ”.
Tivol, E. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547 (1995).
Waterhouse P., Penninger, J. M., Timms E., Wakeham A., Shahinian A., Lee K. P., Thompson C. B., Griesser, H., & Mak T. W. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985-988 (1995).
Perez, V. L. et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6, 411-417 (1997).
Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271. 1734-1736 (1996).
Luhder, F., Hoglund, P., Allison, J. P., Benoist, C. & Mathis, D. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. 187, 427-432 (1998).
Karandikar, N. J., Vanderlugt, C. L., Walunas, T. L., Miller, S. D. & Bluestone, J. A. CTLA-4: A negative regulator of autoimmune disease. J. Exp. Med. 184, 783-788 (1996).
Takahashi, T. et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303-310 (2000).
Judge, T. A. et al. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J. Immunol. 162, 1947-1951 (1999).
Linsley, P. S. et al. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 4, 535-543 (1996).
Alegre, M. L. et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 157, 4762-4770 (1996).
Finn, P. W. et al. Synergistic induction of CTLA-4 expression by constimulation with TCR plus CD28 signals mediated by increased transcrption and messenger ribonucleic acid stability. J. Immunol. 158, 4074-4081 (1997).
Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465 (1995).
Walunas, T. L. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405-413 (1994).
Trowbridge, I. S. & Thomas, M. L. CD45: An emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Ann. Rev. Immunol. 12, 85-116 (1994).
Kashio, N., Matsumoto, W., Parker, S. & Rothstein, D. M. The second domain of the CD45 transmembrane protein tyrosine phosphatase is critical for IL2 secretion and for recruitment of substrates in vivo. J. Biol. Chem. 273, 33856-33863 (1998).
Bottomly, K. et al. A monoclonal antibody to murine CD45R distinguishes CD4 T cell populations that produce different cytokines. Eur. J. Immunol. 19, 617-623 (1989).
Lee, W., Yin, X.-M. & Vitetta, E. Functional and ontogenetic analysis of murine CD45hiand CD45loCD4+T cells. J. Immunol. 144, 3288-3295 (1990).
Powrie, F. et al. Inhibition of Th1 response prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhiCD4+T cells. Immunity 1, 553-562 (1994).
Morimoto, C., Letvin, N. L., Distaso, J. A., Aldrich.W. R. & Schlossman, S. F. The isolation and characterization of the human suppressor inducer T cell subset. J. Immunol. 134, 1508-1515 (1985).
Rothstein, D. M., Yamada, A., Schlossman, S. F. & Morimoto, C. Cyclic regulation of CD45 isoform expression in a long-term human CD4+CD45RA+T cell line. J. Immunol. 146, 1175-1183 (1991).
Sparshott, S. & Bell, E. Membrane CD45R isoform exchange on CD4 T cells is rapid, frequent and dynamic in vivo. Eur. J.Immunol. 24, 2573-2578 (1994).
Michie, C. A., McLean, A., Alcock, C. & Beverly, P. C. L. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 360, 264-265 (1992).
McKenney, D. W., Onodera, H., Gorman, L., Mimura, T. & Rothstein, D. M. Individual isoforms of the CD45 protein tyrosine phosphatase differentially regulate interleukin 2 secretion and activation signal pathways involving Vav in T cells. J. Biol. Chem. 270, 24949-24954 (1995).
Onodera, H., Motto, D.G., Koretzky, G. A. & Rothstein, D. M. Differential Regulation of Activation-Induced Tyrosine Phosphorylation and Recruitment of SLP-76 to Vav by Distinct Isoforms of the CD45 Protein Tyrosine Phosphatase. J. Biol. Chem. 271, 2225-2230 (1996).
Novak, T. et al. Isoforms of the transmembrane tyrosine phosphatase CD45 differentially affect T cell recognition. Immunity 1, 109-119 (1994).
Basadonna, G. et al. Antibody mediated targeting of CD45 isoforms: A novel immunotherapeutic strategy. Proc. Nat. Acad. Sci. USA. 95, 3821-3826 (1998).
Lazárovits, A. et al. Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature 380, 717-720 (1996).
Metz, D. P., Farber, D. L., Taylor, T. & Bottomly, K. Differential role of CTLA-4 in regulation of resting memory versus naive CD4 T cell activation. J. Immunol. 161, 5855-5861 (1998).
Chuang, E. et al. Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression. J. Immunol. 159, 144-151 (1997).
Croft, M., Duncan, D. D. & Swain, S. L. Response of naive antigen-specific CD4+T cells in vitro: characteristics and antigen-presenting cell requirements. J. Exp. Med. 176, 1431-1437 (1992).
Liu, J. et al, Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66, 807-815 (1991).
Walunas, T. L. & Bluestone, J. A. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J. Immunol. 160, 3855-3860 (1998).
Read, S., Malmstrom, V. & Powrie, F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295-302 (2000).
Salomon, B. et al. B7/CD28 constimulation is essential for the homeostasis of the CD4+CD25+immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431-440 (2000).
Perkins, D. et al. Regulation of CTLA-4 expression during T cell activation. J. Immunol. 156, 4154-4159 (1996).
Shiratori, T. et al. Tyrosine phosphorylation controls internalization of CTLA4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity 6, 583-589 (1997).
Schneider, H. et al. Cytolytic T lymphocyte-associated antigen-4 and the TCR /CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2. J. Immunol. 163, 1868-1879 (1999).
Rothstein, D. M., Saito, H., Streull, M., Schlossman, S. F. & Morimoto, C. The alternative splicing of the CD45

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Screening immunomodulatory agents by CTLA-4 upregulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Screening immunomodulatory agents by CTLA-4 upregulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening immunomodulatory agents by CTLA-4 upregulation will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3546155

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.